Results 181 to 190 of about 18,494 (211)

Lipidomics, Microbiota, and Intestinal <i>Clostridioides difficile</i> Infection Outcome. [PDF]

Int J Mol Sci
Branković M, Kraišnik M, Zdravković D, Kraišnik N, Jelić F, Nikolić N, Đurašević S, Tosti T, Gmizić T, Todorović Z.   +9 more
europepmc   +1 more source

Budget Impact Analysis of Fecal Microbiota Spores, Live-brpk (Formerly SER-109) for Recurrent Clostridioides difficile Infection in the United States. [PDF]

Infect Dis Ther
Wilson M, Golan Y, Nguyen D, Yazdani M, Amin AN.   +4 more
europepmc   +1 more source

Fidaxomicin for Clostridioides difficile infection in patients with inflammatory bowel disease: a multicenter retrospective cohort study. [PDF]

J Crohns Colitis
Noviello D, Chaparro M, Viganò C, Blesl A, Barberio B, Yanai H, Orlando A, Ferreiro-Iglesias R, Bezzio C, Zilli A, Molnár T, Gheorghe C, Conforti F, Innocenti T, Saibeni S, Bossuyt P, Oliveira R, Carvalhas Gabrielli AM, Losco A, Vieujean S, Tettoni E, Pirola L, Calderone S, Kornowski Cohen M, Dragoni G, Rath T, Barreiro-de Acosta M, Savarino EV, Gisbert JP, Vecchi M, Atreya R, Caprioli F.   +31 more
europepmc   +1 more source

Risk factors for Clostridioides difficile infection caused by ribotype 027 strains in the Veterans Affairs Healthcare System: a matched case-control study. [PDF]

Antimicrob Resist Infect Control
Silva SY, Wilson BM, Donskey CJ.
europepmc   +1 more source

Influence of Antibiotic Exposure Intensity on the Risk of Clostridioides difficile Infection. [PDF]

Clin Infect Dis
Ray MJ, Strnad LC, Tucker KJ, Furuno JP, Lofgren ET, McCracken CM, Park H, Gerber JS, McGregor JC.   +8 more
europepmc   +1 more source